Profound Medical Announces Proposed Public Offering of Common Shares

Group 1 - Profound Medical Corp. intends to offer and sell common shares in an underwritten public offering, with a 30-day option for underwriters to purchase an additional 15% of the shares sold [1][3] - The net proceeds from the offering are expected to fund the commercialization and development of the TULSA-PRO® and Sonalleve® systems, as well as for working capital and general corporate purposes [2] - The offering is expected to close on or about December 10, 2024, subject to customary closing conditions and necessary approvals [4] Group 2 - A preliminary prospectus supplement has been filed, and a subsequent prospectus supplement will be filed in accordance with securities regulations in Canada and the United States [5][6] - The common shares are being offered under the prospectus supplement, which will be accessible on SEDAR+ and EDGAR [6] - Profound Medical Corp. is a commercial-stage medical device company that develops incision-free therapies for the ablation of diseased tissue, including the TULSA-PRO® and Sonalleve® systems [9]